Exact Sciences Completes Modular PMA For Cologuard
This article was originally published in The Gray Sheet
Executive Summary
The molecular diagnostics manufacturer submitted the final module of its PMA for Cologuard and expects to request Medicare coverage later this year through the FDA-CMS parallel review process.
You may also be interested in...
Research Briefs: Studies From Exact Sciences, EndoChoice; Neuroimaging Overuse
In the lead up to an FDA panel, positive data is published for Exact Science’s Cologuard multi-target stool DNA-based screening test. EndoChoice’s Fuse endoscope sees more colon cancer than traditional endoscopes. Overuse of neuroimaging for headaches documented. Long-term study finds high-frequency oscillatory ventilation is better for premature babies than standard ventilation. Drug-coated balloon trial.
News Briefs: 23andMe’s Mea Culpa; FDA Reaches Settlement With J&J; Meaningful Use Delay
Genetic testing firm 23andMe has stopped providing its genetic tests to consumers, following a warning letter from FDA. The agency has reached a $1.25 million settlement with Johnson & Johnson’s Advanced Sterilization Products group. HHS agencies announced delay in health IT meaningful use implementation. More news.
Research In Brief
Exact Sciences’ and Genomic Health announce favorable results for colon cancer tests. Boston Scientific launches trial of MRI-safe pacemaker. More research news.